Skip to main content
. 2021 Mar 9;67(3):1007–1017. doi: 10.1007/s10620-021-06907-5

Table 2.

Previous and concomitant therapies [n (%)]

Previous Week 0 Week 14 Week 54
5-asa 95 (99) 59 (61.5) 61 (67) 50 (69.4)
Steroids 91 (94.8) 62 (64.6) 31 (34.1) 5 (6.9)
Thiopurines 57 (59.4) 18 (18.8) 15 (16.5) 10 (13.9)
anti-TNF 37 (38.5)
Infliximab 27 (28.1)
Adalimumab 10 (10.4
Golimumab 11 (11.5)

Percentages refer to 96 patients for previous treatments and week 0, 91 patients for week 14, and 72 patients for week 54